| General Recommendations | Anticoagulation | Testing/Triage | Other (Long COVID, Vaccine, Steroids) |
|---|
| Key Definitions and Frameworks | - includes evaluation of quality of evidence
- also needs to address processing of real world evidence
- [weave in ICER - search ISER opioids]
|
|
|
|
| What to know/do Overview | - For people creating evidence syntheses
- See if work on planned topic has been done already - search L*VE/Epistemonikos (2K reviews - cover many questions - only a fraction registered in PROSPERO; most reviews are out of date - only 3% have all the trials they should), PROSPERO for what's in the pipeline. Make sure that any existing reviews look at outcomes that are pertinent to your needs [leverage COMET - outcome measures], etc. that of interest for the need at hand. Very hard for user to identify a review that's up to date. COVID-END repository of Best Evidence Syntheses can be helpful here.
- Need to have access to raw data that fed into the review so it's more re-usable.
- important to understand end-user needs so that the review can be aimed at addressing them
- AHRQ has methods guides, Cochrane has them. Are there tools for this on COVID - e.g., Resources and tools for researchers considering and conducting
COVID-19 evidence syntheses (From COVID-END Synthesizing WG)
- For organizations consuming evidence syntheses
- For selecting/using synthesized evidence: Is there a GRADE evidence profile? Do they make quality assessments? How comprehensive are they? Search date
|
|
|
|
| Input Sources | | | |
|
| Output Repositories | |
|
|
|
| Standards | |
|
|
|
| Initiatives |
|
|
| |
| Tools/ Platforms | |
|
|
|
| Other Best Practices | - COVID-NMA has initiated communication with all trialists to try to ensure consistent approaches e.g. selection of outcomes, reduction of risk of bias, and to invite them to contribute missing data.
- Framework slides: Applying Standards to the Evidence Domain (from the COKA Evidence Ecosystem Liaison WG)
|
|
|
|